[go: up one dir, main page]

ZA200900708B - Use of WNT5A for inhibiting scarring - Google Patents

Use of WNT5A for inhibiting scarring

Info

Publication number
ZA200900708B
ZA200900708B ZA200900708A ZA200900708A ZA200900708B ZA 200900708 B ZA200900708 B ZA 200900708B ZA 200900708 A ZA200900708 A ZA 200900708A ZA 200900708 A ZA200900708 A ZA 200900708A ZA 200900708 B ZA200900708 B ZA 200900708B
Authority
ZA
South Africa
Prior art keywords
wnt5a
inhibiting scarring
scarring
inhibiting
Prior art date
Application number
ZA200900708A
Other languages
English (en)
Inventor
Mark William James Ferguson
Hugh Gerard Laverty
Nicholas Occleston
Sharon O'kane
Goldspink Nicholas Nield
Original Assignee
Renovo Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Renovo Ltd filed Critical Renovo Ltd
Publication of ZA200900708B publication Critical patent/ZA200900708B/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Zoology (AREA)
  • Urology & Nephrology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Psychiatry (AREA)
  • Rheumatology (AREA)
  • Pulmonology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Endocrinology (AREA)
  • Reproductive Health (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
ZA200900708A 2006-06-30 2007-06-29 Use of WNT5A for inhibiting scarring ZA200900708B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0613031.4A GB0613031D0 (en) 2006-06-30 2006-06-30 Medicaments

Publications (1)

Publication Number Publication Date
ZA200900708B true ZA200900708B (en) 2010-05-26

Family

ID=36888398

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200900708A ZA200900708B (en) 2006-06-30 2007-06-29 Use of WNT5A for inhibiting scarring

Country Status (11)

Country Link
US (1) US20100137201A1 (xx)
EP (1) EP2046364A2 (xx)
JP (1) JP2009542609A (xx)
CN (1) CN101511383A (xx)
AU (1) AU2007263593A1 (xx)
BR (1) BRPI0713807A2 (xx)
CA (1) CA2656965A1 (xx)
GB (1) GB0613031D0 (xx)
MX (1) MX2008016520A (xx)
WO (1) WO2008001113A2 (xx)
ZA (1) ZA200900708B (xx)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0702930D0 (en) * 2007-02-15 2007-03-28 Renovo Ltd Medicaments and methods for inhibition of scarring
WO2009047330A1 (en) * 2007-10-12 2009-04-16 Universite Louis Pasteur Use of wnt5a for treating or preventing obesity and atherosclerosis
CN101790221B (zh) * 2009-01-22 2015-05-06 中兴通讯股份有限公司 家用基站切换时网络接入控制方法及系统
EP2226080A1 (en) * 2009-03-05 2010-09-08 Universiteit Maastricht Antagonistic peptides for frizzled-1 and frizzled-2
KR20200042912A (ko) * 2017-08-20 2020-04-24 더 리젠트스 오브 더 유니이버시티 오브 캘리포니아 녹내장을 치료하기 위한 Wnt5a의 조절

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6485972B1 (en) * 1998-10-15 2002-11-26 President And Fellows Of Harvard College WNT signalling in reproductive organs
IL152785A0 (en) * 2000-05-12 2003-06-24 Univ Utah Res Found Compositions and methods for cell dedifferentiation and tissue regeneration
US20040087016A1 (en) * 2000-05-12 2004-05-06 University Of Utah Research Foundation Compositions and methods for cell dedifferentiation and tissue regeneration
WO2002097032A2 (en) * 2001-04-06 2002-12-05 Incyte Genomics, Inc. Proteins associated with cell growth, differentiation, and death
AU2003293013A1 (en) * 2002-11-21 2004-06-18 University Of Massachusets Diagnosing and treating hematopoietic cancers
EP1622637A2 (en) * 2003-05-15 2006-02-08 The University of Chicago Method and compositions for nerve regeneration
EP1737948A2 (en) * 2004-04-16 2007-01-03 Hydra Biosciences, Inc. Methods of promoting cardiac cell proliferation
WO2006026652A2 (en) * 2004-08-30 2006-03-09 Iken Tissue Therapeutics, Inc. Conditioned medium comprising wnt proteins to promote repair of damaged tissue

Also Published As

Publication number Publication date
US20100137201A1 (en) 2010-06-03
WO2008001113A3 (en) 2008-03-13
AU2007263593A1 (en) 2008-01-03
JP2009542609A (ja) 2009-12-03
WO2008001113A2 (en) 2008-01-03
BRPI0713807A2 (pt) 2012-11-06
CA2656965A1 (en) 2008-01-03
EP2046364A2 (en) 2009-04-15
CN101511383A (zh) 2009-08-19
MX2008016520A (es) 2009-04-01
GB0613031D0 (en) 2006-08-09

Similar Documents

Publication Publication Date Title
EP2026843A4 (en) THERAPEUTIC USES OF RTP801L INHIBITORS
PT2397142T (pt) Utilizações de inibidores da dpp iv
PL2005757T3 (pl) Wydajne kodowanie wielu widoków
ZA201004724B (en) Methods for inhibiting scarring
SI2383271T1 (sl) Aminokinoloni kot inhibitorji gsk-3
GB0912562D0 (en) LXR-antagonists for the prevention, reduction or inhibition of scarring
IL194494A0 (en) Thiazolyldihydrocyclopentapyrazoles for use as pi3-kinase inhibitors
IL197632A0 (en) Use of jam-c binding compounds
GB0621607D0 (en) Inhibitors of c-Met
GB0622084D0 (en) Inhibitors of HSP90
IL196606A0 (en) Use of escin
IL192700A0 (en) Use of elderberry extract
ZA200900708B (en) Use of WNT5A for inhibiting scarring
IL197192A0 (en) Preparation of decahalodiphenyl ethane
GB0621205D0 (en) Inhibitors of PLK
GB0724204D0 (en) Methods for inhibition of scarring
HK1124259A (en) Use of wnt5a for inhibiting scarring
ZA201004090B (en) Methods for the inhibition of scarring
TWI366558B (en) Mono-nitration of aromatic compounds
GB0624439D0 (en) Technique for treatment of gall-and kidney-stones
GB0625381D0 (en) Novel inhibitors of flaviridae
GB0724237D0 (en) Methods for inhibiting scarring
HK1135610A (en) Wnt3a for inhibition of scarring
IL198836A0 (en) Processes for preparation of 9-haloacetamidomidominocyclines
GB0622085D0 (en) Inhibitors of HSP90